Coronavirus Drug and Vaccine Studies Are Recruiting Their First Volunteers

This study, says Kalil, is also designed to be more flexible than most drug trials. “This is not just a remdesivir trial,” he says. “It will test as many [COVID-19] therapies as possible, and remdesivir is just the first. Let’s say a couple of months from now, we realize that remdesivir is a good drug, that it works better than placebo…. Then patients receiving the placebo would be offered the drug and we would move on to test another drug. If remdesivir turns out not to be effective, then we would remove it from the study and bring another drug to test against placebo. It’s a dynamic, fast way to run a randomized trial.” The design is a way to accelerate testing of antiviral drugs against COVID-19, since infections are on-going and there is no treatment yet. Meanwhile, other labs are working on developing vaccines that would provide some protection against the virus in the first place. The vaccine study that is furthest along (and which is also overseen by NIAID) is currently recruiting its first participants at Kaiser Permanente Washington Health Research Institute. Unlike the remdesivir trial, this study will enroll healthy volunteers. Dr. Lisa Jackson, lead investigator on the study, says 45 healthy people will be recruited to test three different doses of the vaccine. Kaiser is currently getting thousands of daily online requests from people interested in participating. Researchers are contacting the volunteers by phone to asse...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Infectious Disease Source Type: news

Related Links:

Authors: Barber MRW, Clarke AE Abstract INTRODUCTION: Systemic lupus erythematosus (SLE) is an autoimmune disorder that affects almost every organ system and it is treated with immunomodulation and immunosuppression. SLE patients have an intrinsically dysfunctional immune system which is exacerbated by disease activity and leaves them vulnerable to infection. Treatment with immunosuppression increases susceptibility to infection, while hydroxychloroquine use decreases this risk. Infectious diseases are a leading cause of hospitalization and death. AREAS COVERED: This narrative review provides an overview of rec...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
Cases in Africa pass 150,000; Germany eases travel ban;Wuhan doctor who worked with whistleblower diesGermany lifts travel warning for EuropeChina withheld data on coronavirus from WHO, recordings reveal‘We can’t relax’: Europeans face up to life after lockdownUK coronavirus updates – liveCoronavirus latest: at a glance9.00pmBSTKey developments in the globalcoronavirus outbreak today include:8.52pmBSTThe USA has confirmed 14,790 more cases and 761 more deaths in the past 24 hours, according to the Centers for Disease Control and Prevention (CDC). That takes the cumulative totals to 1,802,470 and 105...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Coronavirus outbreak World news Infectious diseases Science Microbiology Medical research UK news US news Australia news Source Type: news
Athletes who test positive for SARS-CoV-2, the virus that causes COVID-19, should take at least two weeks off from intense or competitive exercise and even more if they show signs of myocarditis, according to two new reports.Reuters Health Information
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Infectious Diseases News Source Type: news
Infants with symptomatic COVID-19 infection harbor higher SARS-CoV-2 viral loads in the nose at presentation but develop less severe disease as compared to older children and adolescents, report clinicians from New York City.Reuters Health Information
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Pediatrics News Source Type: news
Authors: Alanagreh L, Alzoughool F, Atoum M Abstract The emerging COVID-19 pandemic poses a threat to the global health care system. Given the lack of antiviral therapies or vaccines for the disease, the antimalarial drug hydroxychloroquine (HCQ) obtained much attention as a treatment for COVID-19. However, there are limited and uncertain clinical data to support the beneficial effect of this drug in COVID-19 treatment. HCQ has several side effects and warnings, including blindness, heart failure, and renal toxicity, even with recommended doses. For severe cases of COVID-19 or in patients with preexisting condition...
Source: International Journal of Risk and Safety in Medicine - Category: Drugs & Pharmacology Tags: Int J Risk Saf Med Source Type: research
Authors: Doggrell SA Abstract INTRODUCTION: Lopinavir in combination with ritonavir is approved for the treatment of HIV and has recently been subject to a clinical trial in severe Covid-19. AREAS COVERED: This evaluation is of LOTUS China (the Lopinavir Trial for Suppression of SARS-Cov-2 in China), which was a randomised trial in hospitalised subjects with Covid-9 in a respiratory sample and pneumonia. As, in severe Covid-19, lopinavir/ritonavir had no beneficial effects but increased gastrointestinal adverse effects, this combination should not be used at this stage of Covid-19. EXPERT OPINION: In my opi...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
This study showed that a five-day regimen is as effective as 10 days–that’s important, doctors say, since it could mean shorter stays in the hospital, which could alleviate some of the burden on the health care system. “Of course we will have to wait for the final review of all the data, but it would be very nice to have an anti-viral that’s efficacious in this terrible illness,” says Dr. Aruna Subramanian, a clinical professor of medicine at Stanford and an investigator on the study. “At least we know that we can help patients with this, and that’s really the bottom line.” T...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 feature Magazine Source Type: news
Gilead, a California-based biopharmaceutical company, released two encouraging reports about remdesivir, an experimental drug that is being tested as a COVID-19 treatment. In one statement, the company said that a large study of remdesivir “met its primary endpoint”: meaning, in this case, that the researchers have concluded that hospitalized patients taking the drug appear to improve faster than patients given a placebo. The study is run by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health and involves severe patients at multiple centers across th...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
Cases of a novel pneumonia-like illness that originated in Wuhan, China in December have now been confirmed in South Korea, Thailand, Japan, Taiwan, Macau—and, as of Jan. 21, the U.S. The virus’ geographic reach, as well as its newly discovered ability to spread via person-to-person contact, has health officials worried about the prospect of globals spread. As health officials scramble to learn more about the virus and is origins, researchers are simultaneously turning to the question of how to develop a vaccine or therapy that could help contain transmission worldwide—a feat that experts say is technical...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Infectious Disease Source Type: news
More News: Allergy | Allergy & Immunology | Coronavirus | COVID-19 | Ebola | Ebola Vaccine | Health | Infectious Diseases | Italy Health | Japan Health | MERS | Pneomococcal Vaccine | Pneumonia | SARS | Study | Vaccines | Veterinary Vaccinations